The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Delivery of peri-operative chemotherapy for muscle-invasive bladder cancer (MIBC) in routine clinical practice: Does regimen and timing matter?
Christopher M. Booth
No relevant relationships to disclose
D. Robert Siemens
No relevant relationships to disclose
Yingwei Peng
No relevant relationships to disclose
Ian Tannock
No relevant relationships to disclose
William J. Mackillop
No relevant relationships to disclose